Innate Pharma SA (the “Company” – Euronext Paris: FR0010331421 – IPH), announces that it will host an event for analysts and investors in London to discuss the Company’s corporate strategy and ongoing programs, science and R&D strategy.
Hervé Brailly, CEO and Co-Founder, Nicolai Wagtmann, CSO and Pierre Dodion, CMO, will host a presentation and lunch at 12.00 BST on Wednesday 13 July 2016 at the offices of Consilium Strategic Communications, 41 Lothbury, London, EC2R 7HG.
If you would like to attend the event, please contact Consilium Strategic Communications at InnatePharma@consilium-comms.com or +44 (0)20 3709 5700. For those who are unable to attend in person, a live webcast and replay will be accessible at the following link: https://arkadinemea-events.adobeconnect.com/innate-pharma/event/registration.html
A replay of the webcast will be made available on the “Innate Live” section of the website shortly after the event.
About Innate Pharma:
Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells.
The Company’s aim is to become a fully-integrated biopharmaceutical company in the area of immuno-therapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma’s innovative approach has resulted in three first-in-class, clinical-stage therapeutic antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases.
The Company’s expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb and Sanofi.
Based in Marseille, France, Innate Pharma has more than 120 employees and is listed on Euronext Paris.
Practical Information about Innate Pharma shares:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website ( http://www.amf-france.org ) or on Innate Pharma’s website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
|Innate Pharma||Press Contacts|
Director, Investor Relations
|ATCG Press (France)
|Tel.: +33 (0)4 30 30 30 87||Mob: +33 (0)6 10 54 36 72|
|Consilium Strategic Communications (ROW)|
|Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Hendrik Thys
|Tel.: +44 (0)20 3709 5700|
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Apr 03, 2017 0